The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | MRD status after liso-cel in the TRANSCEND-CLL-004 trial
Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the MRD status of relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) patients after lisocabtagene maraleucel treatment in the TRANSCEND-CLL-004 trial (NCT03331198). She also discusses the next stages for the trial, which will also look at combining the agent with ibrutinib. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
